


Singapore's Hyphens Pharma and Medac expands subcutaneous autoinjector pen into Thailand and Cambodia markets

16 October 2025 | News

Metoject® autoinjector pen to further strengthens its footprint in Southeast Asia



Hyphens Pharma Pte. Ltd., a subsidiary of Hyphens Pharma International Limited, Singapore's leading specialty pharmaceutical and consumer healthcare group **"Hyphens Pharma"** has extended its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. ("**medac**") to include Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.

This territory extension builds upon the existing agreement signed in March 2025, which granted Hyphens Pharma exclusive rights to register and commercialise the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam. With the inclusion of Thailand and Cambodia, Hyphens Pharma further strengthens its footprint in Southeast Asia, reinforcing its commitment to bringing innovative treatments across the region.

The Metoject® subcutaneous autoinjector pen is currently approved and available in over 15 countries in Europe, the United States and Japan, and well-recognised as a first-line treatment for rheumatoid arthritis under both the European and American guidelines.¹ The subcutaneous methotrexate injection treatment is indicated for patients with rheumatoid arthritis and plaque psoriasis, offering a therapeutic option with better bioavailability and reduced gastrointestinal side effects compared to oral methotrexate.